Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model
- PMID: 12009868
- DOI: 10.1006/viro.2001.1345
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model
Abstract
Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.
Similar articles
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005. J Virol. 2005. PMID: 16160159 Free PMC article.
-
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9. Vaccine. 2012. PMID: 22234262 Free PMC article.
-
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65. doi: 10.1089/0889222041217419. AIDS Res Hum Retroviruses. 2004. PMID: 15242543
-
Developing DNA vaccines against immunodeficiency viruses.Curr Top Microbiol Immunol. 1998;226:161-73. doi: 10.1007/978-3-642-80475-5_10. Curr Top Microbiol Immunol. 1998. PMID: 9479841 Review. No abstract available.
-
Development of a DNA-MVA/HIVA vaccine for Kenya.Vaccine. 2002 May 6;20(15):1995-8. doi: 10.1016/s0264-410x(02)00085-3. Vaccine. 2002. PMID: 11983261 Review.
Cited by
-
Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.Vaccine. 2012 Aug 10;30(37):5453-8. doi: 10.1016/j.vaccine.2012.06.074. Epub 2012 Jul 6. Vaccine. 2012. PMID: 22776214 Free PMC article.
-
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Virology. 2008 Mar 15;372(2):260-72. doi: 10.1016/j.virol.2007.10.033. Epub 2007 Nov 28. Virology. 2008. PMID: 18048074 Free PMC article.
-
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?Curr Opin Biotechnol. 2004 Dec;15(6):506-12. doi: 10.1016/j.copbio.2004.09.001. Curr Opin Biotechnol. 2004. PMID: 15560976 Free PMC article. Review.
-
Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Vaccine. 2010 Feb 10;28(6):1481-92. doi: 10.1016/j.vaccine.2009.11.061. Epub 2009 Dec 6. Vaccine. 2010. PMID: 19995539 Free PMC article.
-
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Virology. 2007 Sep 15;366(1):84-97. doi: 10.1016/j.virol.2007.02.041. Epub 2007 May 11. Virology. 2007. PMID: 17499326 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials